MDX Life Sciences

What MDX Life Sciences does

MDX Life Sciences is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Newton, Massachusetts, with an additional research office in Ramat Gan, Israel. The company operates two programs: a commercialized patient monitoring platform, MDXViewer, and an early-stage autologous mitochondrial transplantation pipeline for tissue and organ regeneration. The company employs 11-50 people and does not disclose revenue, funding, or institutional investors.

MDXViewer is an FDA-cleared, multiparametric bedside monitoring system that uses low-power light illumination of tissue via a disposable optical fiber probe integrated into a 3-way Foley catheter. The system simultaneously measures mitochondrial NADH redox state, microcirculatory blood flow, microcirculatory blood oxygenation, and tissue reflectance, and aggregates these into a proprietary Tissue Metabolic Score intended to provide earlier warning of metabolic decompensation than systemic vital signs (BP, CVP, CO) used in current ICU and OR practice. A second program targets autologous mitochondrial transplantation to treat myocardial ischemia, reperfusion injury, and related ischemic disorders.

MDX Life Sciences generates revenue, to the extent it does, through sale or rental of the MDXViewer capital equipment and recurring disposable probe consumables to hospitals, with primary call points in intensive care units and operating rooms and a secondary focus on cardiovascular and cardiothoracic surgery. The go-to-market is enterprise field sales engaging hospital procurement and clinical leadership, supported by a portfolio of peer-reviewed scientific publications rather than broad marketing campaigns. Pricing is not publicly disclosed and is structured around facility-level capital equipment quotes with recurring consumable economics.

Name

MDX Life Sciences

Legal name

MDX LIFESCIENCES, Inc.

Website

https://mdxlifesciences.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

MDX Life Sciences is a clinical-stage biotechnology company developing autologous mitochondrial transplantation for tissue and organ regeneration and commercializing the FDA-cleared MDXViewer real-time tissue metabolic monitoring system for hospitals' ICUs, operating rooms, and cardiovascular surgery.

Ownership category

akta.pro rank

Product category

Critical Care Patient Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)

akta.pro secondary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

Keywords

• Patient monitoring systems
• Tissue metabolic monitoring
• Mitochondrial transplantation
• Critical care devices
• Biotechnology medical devices

Headquarters

HQ city

Newton

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. MDXViewer Medical Device Sales/Rental: MDX Life Sciences generates revenue through the sale or rental of its MDXViewer patient monitoring system to healthcare facilities including intensive care units and operating rooms. The company offers both the main monitoring unit and disposable probe accessories, creating an ongoing revenue stream from consumables used with each patient monitoring session.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

MDX Life Sciences develops and commercializes the MDXViewer, an FDA-cleared multiparametric patient monitoring system that uses low-power light illumination and fiber-optic probes to continuously measure mitochondrial NADH redox state, microcirculatory blood flow, microcirculatory blood oxygenation, and tissue reflectance in real time, providing a Tissue Metabolic Score for ICU and operating room use. The company is also clinically developing autologous mitochondrial transplantation therapies for tissue and organ regeneration, including cardiovascular applications.

Product overview

MDX Life Sciences is a clinical-stage biotechnology company with a single primary product offering: MDXViewer, a patient monitoring system. MDXViewer is an adjunctive bedside monitoring device designed for intensive care, operating rooms, and emergency care settings. The system analyzes physiological activities at the tissue level and integrates with systemic vital signs, providing early identification of metabolic imbalances through a Tissue Metabolic Score. The device consists of three components: a main unit (light sources, optical detectors, signal processing), a monitor unit (display and user interface), and a probe accessory (optical fiber bundle integrated into a urinary catheter). The company is also developing autologous mitochondrial transplantation for tissue and organ regeneration.

Differentiator

Problem solved

Functional benefit

Brands

• MDXViewer: First generation patient monitoring system providing real-time continuous information via four physiological parameters sensed at tissue level. Used in intensive care, operating suits, and emergency care settings for early identification of metabolic imbalances.

Products and services

• MDXViewer (MXV) The MDXViewer is a bedside patient monitoring system that uses low-power light illumination of tissue via a disposable urethral wall probe integrated into a 3-way Foley catheter to simultaneously measure four physiological parameters: mitochondrial NADH redox state, microcirculatory blood flow (TBF), microcirculatory blood oxygenation, and tissue reflectance. These are translated into a Tissue Metabolic Score providing real-time continuous assessment of tissue metabolic state. The system consists of a main unit (light sources, optical detectors, signal processing), a monitor unit with display, and disposable fiber-optic probes. It is designed for use by ICU clinicians, anesthesiologists, and surgeons in intensive care units, operating rooms, and emergency care settings.

Quantifiable outcome

• MDXViewer enables early identification/warning of body's critical metabolic imbalances before they manifest systemically

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Medical Community PartnersOthersMDX Life Sciences maintains membership in good standing with various medical and healthcare organizations. The company engages with the clinical and scientific community through publications and research collaborations, though specific named partners are not detailed on the company website.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MDX Life Sciences